You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC

Test Your Knowledge of Gene Therapy for Hemophilia

  • Authors: John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH
  • CME / ABIM MOC Released: 5/3/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 5/3/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists, pediatricians, and other healthcare professionals who manage patients with hemophilia.

The goal of this activity is to review the latest developments in gene therapy for patients with hemophilia.

Upon completion of this activity, participants will have increased knowledge regarding the:

  • Research on gene therapy in hemophilia
  • New findings from clinical trials on gene therapy in hemophilia


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH

    Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, London, United Kingdom

    Disclosures

    Disclosure: John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam Pharmaceuticals, Inc; Biogen; BioMarin Pharmaceutical Inc.; Octapharma; Roche; Shire; Swedish Orphan Biovitrum
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Biotest; Novo Nordisk; Pfizer Inc

    Dr Pasi does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Pasi does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Charlotte Warren

    Senior Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

  • Melinda Tanzola, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Melinda Tanzola has disclosed no relevant financial relationships.

Steering Committee

  • John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH

    Disclosures

    As listed above.

  • Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

    Professor of Haematology, Faculty of Health Sciences, Department of Molecular Medicine and Haematology, University of the Witwatersrand; Head of Clinical Haematology Ward and Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa

    Disclosures

    Disclosure: Johnny Mahlangu, BSc, MBBCh, MMed, FCPath, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Bayer HealthCare; Biotest; Biogen; Baxalta; CSL Behring; Catalyst Pharmaceutical Partners, Inc.; Novo Nordisk; Roche; Spark
    Served as a speaker or a member of a speakers bureau for: Alnylam Pharmaceuticals, Inc; Bayer HealthCare; Biotest; Biogen; Novo Nordisk; Pfizer Inc.; Swedish Orphan Biovitrum; Shire; Roche
    Received grants for clinical research from: Bayer HealthCare; Biogen; BioMarin Pharmaceutical Inc.; CSL Behring; Novo Nordisk; Swedish Orphan Biovitrum; Roche; Unique Pharmaceuticals

  • Margareth C. Ozelo, MD, PhD

    Assistant Professor; Director, IHTC Hemocentro UNICAMP, University of Campinas; Director, WFH International Hemophilia Training Center, Sao Paulo, Brazil

    Disclosures

    Disclosure: Margareth C. Ozelo, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BioMarin Pharmaceutical Inc.; CSL Behring; Novo Nordisk; Pfizer Inc.; Roche; Shire
    Served as a speaker or a member of a speakers bureau for: BioMarin Pharmaceutical Inc.; Grifols; Novo Nordisk; Pfizer Inc.; Roche; Shire
    Received grants for clinical research from: Bioverativ; Pfizer Inc.; Shire

  • Flora Peyvandi, MD, PhD

    Professor of Internal Medicine, University of Milan; Director, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

    Disclosures

    Professor of Internal Medicine, University of Milan; Director, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy Disclosure: Flora Peyvandi, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Kedrion Biopharma Inc.; LFB SA
    Served as a speaker or a member of a speakers bureau for: Ablynx; Alnylam Pharmaceuticals, Inc; F. Hoffmann-La Roche; Grifols; Shire; Swedish Orphan Biovitrum
    Other: Advisory board member for Ablynx; F. Hoffmann-La Roche; Shire

  • Steven W. Pipe, MD

    Professor of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, United States

    Disclosures

    Disclosure: Steven W. Pipe, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam Pharmaceuticals, Inc; Bayer HealthCare; BioMarin Pharmaceutical Inc.; Bioverativ; CSL Behring; Novo Nordisk; Pfizer Inc.; Roche; Spark; UniQure
    Received grants for clinical research from: Pfizer Inc.; Siemens Healthcare Diagnostics Inc.; Shire

  • Ulrike M. Reiss, MD

    Associate Member; Director of Clinical Hematology; Director, Pediatric Hemophilia Treatment Center, Department of Hematology, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States

    Disclosures

    Disclosure: Ulrike M. Reiss, MD, has disclosed no relevant financial relationships.

Additional Planners

  • Amanda Bok

    Course Director, Chief Executive Officer, European Haemophilia Consortium (EHC), Brussels, Belgium

    Disclosures

    Disclosure: Amanda Bok has disclosed no relevant financial relationships.

  • Neil Frick, MS

    Course Director, Vice President for Medical Programs and Information, National Hemophilia Foundation, New York, New York.

    Disclosures

    Disclosure: Neil Frick, MS, has disclosed no relevant financial relationships.

  • Fiona Robinson, PhD

    Course Director, Educational Materials Manager, World Federation of Hemophilia (WFH), Montreal, Quebec

    Disclosures

    Disclosure: Fiona Robinson, PhD, has disclosed no relevant financial relationships.

  • Georghia Michael, PhD

    Medical Writing Consultant, World Federation of Hemophilia (WFH), Montreal, Quebec

    Disclosures

    Disclosure: Georghia Michael, PhD, has disclosed the following relevant financial relationships:
    Owns stock, stock options, or bonds from: GlaxoSmithKline plc.

CME Reviewer

  • Amy H. Seung, PharmD, BCOP

    Disclosures

    Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BeyondSpring Pharmaceuticals

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Test Your Knowledge of Gene Therapy for Hemophilia

Authors: John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCHFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 5/3/2018

Valid for credit through: 5/3/2019

processing....

The goals of continuing medical education (CME) and professional development are to acquire and retain knowledge that will enhance clinical practice and improve patient outcomes. The following self-assessment survey is offered for CME credit and is designed to test your current knowledge and skills related to gene therapy in hemophilia.

  • Print